← All news
Markets
Beam reports 18-month data for AATD gene therapy BEAM-302
2 outlets - including Investing and Seekingalpha - are covering this story.
Covered by 2 outlets
All coverage · 3 articles
Seeking Alpha
·Sep 8, 17:15 UTC
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Investing.com Canada
·Sep 8, 10:06 UTC
Beam reports 18-month data for AATD gene therapy BEAM-302
Investing.com News
·Sep 8, 10:04 UTC